Business Wire

CA-SYSDIG

13.1.2022 17:56:06 CET | Business Wire | Press release

Share
​​Creator of Wireshark Joins Sysdig to Extend the Open Source Project for Cloud Security

Sysdig, Inc., the unified container and cloud security leader, today announced that Gerald Combs, the Wireshark creator and project leader, has joined the company. Wireshark, an open source tool, is the world’s foremost and widely-used traffic protocol analyzer with more than 60 million downloads in the last 5 years, an average of one million per month. Loris Degioanni, CTO and Founder of Sysdig, partnered with Gerald to launch Wireshark more than 15 years ago. Gerald joins Sysdig’s open source team, which is a significant contributor to many open source projects, including Falco, eBPF, Sysdig open source, Sysdig Inspect, and other tools and libraries. With Gerald joining, Sysdig assumes responsibility for sponsoring and managing the Wireshark community and extending Wireshark’s use cases to the cloud ecosystem.

Wireshark is an open source GUI network package capturing tool that enables teams to monitor network traffic, learn protocols and packet basics, and troubleshoot network problems. For network admins, Wireshark is the de facto standard for checking health and security at a microscopic level. Wireshark takes packet captures and saves them for later viewing. Teams can filter through that traffic to find evidence from an incident. With more than 1,900 contributors, the number of integrations continues to expand. Adoption is broad as Wireshark can be used consistently across nearly any environment, including Windows, Linux, and macOS, among others.

“It’s amazing to see the lasting heritage of Wireshark, led by Gerald. You can guarantee most of the Fortune 2000 are actively using Wireshark,” said Loris Degioanni, CTO and Founder, Sysdig. “I am excited to be reunited with Gerald and to advance the project in the same way Sysdig supports Falco and the Sysdig open source project. This move ensures Wireshark will continue to innovate. Our goal at Sysdig is to empower Wireshark.”

The Importance of Healthy Open Source Projects

The Log4j and OpenSSL vulnerabilities have shown that large and small organizations rely on open source projects and major issues arise when critical vulnerabilities are found in these tools. Log4j spotlighted the importance of maintaining open source projects. Continuing to maintain the project’s health is of the utmost importance considering the widespread adoption of Wireshark.

The Wireshark Story

While studying network analyzers and creating a popular open source tool while working on his PhD in Italy, Loris was invited to the United States to do research on packets, which is where he met Gerald. Gerald joined Loris at CACE Technologies in the early 2000’s, where they collaborated and grew Wireshark. CACE Technologies was later acquired and since that time, Gerald has focused on growing the tool and ensuring Wireshark and its community have the resources needed to thrive.

“I am excited to be reunited with Loris and explore the opportunity we have to expand Wireshark to the cloud,” said Gerald Combs, Director of Open Source Projects, Sysdig. “My move to Sysdig and the subsequent move for Wireshark will give Wireshark the corporate sponsor it needs to continue moving forward. This is a significant milestone for Wireshark and with Sysdig’s backing, we will have the assistance we need to continue to evolve use cases for Wireshark.”

The Wireshark Future

Sysdig will ensure the community has the backing it needs, including supporting Gerald as the leader of the community, ensuring Wireshark has the resources needed to operate, and sponsoring SharkFest. Sysdig has an open source team that will contribute to Wireshark. Reunited, Gerald and Loris will investigate new innovative ways to address challenges with securing the cloud.

Sysdig’s Commitment to Open Source

Sysdig was founded as an open source company and the Sysdig platform was built on an open source foundation to address the security challenges of modern cloud applications. Open source Sysdig and Falco are projects that were created by Sysdig to leverage deep visibility as a foundation for security, and they have become standards for container and cloud threat detection and incident response. Falco, which was contributed to the CNCF in 2018, is now an incubation-level hosted project with more than 40 million downloads.

Resources

About Sysdig

Sysdig is driving the standard for securing the cloud, empowering organizations to confidently secure containers, Kubernetes, and cloud services. The Sysdig platform enables teams to secure the build, detect and respond to runtime threats, and continuously manage cloud configurations, permissions and compliance. Sysdig is a SaaS platform built on an open source stack that includes Falco and Sysdig open source, the open standards for runtime threat detection and response. The largest and most security conscious companies rely on Sysdig for container and cloud security. sysdig.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye